Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
06 2020
Historique:
received: 11 10 2019
revised: 06 04 2020
accepted: 06 04 2020
entrez: 19 4 2020
pubmed: 19 4 2020
medline: 8 7 2021
Statut: epublish

Résumé

Ubiquitin and the ubiquitin-like SUMO are covalently conjugated to thousands of proteins to modulate their function and fate. Many of the enzymes involved in their conjugation are dysregulated in cancers and involved in cancer cell response to therapies. We describe here the identification of biomarkers of the activity of these enzymes and their use to predict acute myeloid leukemias (AML) response to standard chemotherapy (daunorubicin-DNR and cytarabine-Ara-C). We compared the ability of extracts from chemosensitive and chemoresistant AML cells to conjugate ubiquitin or SUMO-1 on 9,000 proteins spotted on protein arrays. We identified 122 proteins whose conjugation by these posttranslational modifiers marks AML resistance to DNR and/or Ara-C. Based on this signature, we defined a statistical score predicting AML patient response to standard chemotherapy. We finally developed a miniaturized assay allowing for easy assessment of modification levels of the selected biomarkers and validated it in patient cell extracts. Thus, our work identifies a new type of ubiquitin-based biomarkers that could be used to predict cancer patient response to treatments.

Identifiants

pubmed: 32303586
pii: 3/6/e201900577
doi: 10.26508/lsa.201900577
pmc: PMC7167290
pii:
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Antimetabolites, Antineoplastic 0
Biomarkers, Tumor 0
SUMO-1 Protein 0
Ubiquitin 0
Cytarabine 04079A1RDZ
Daunorubicin ZS7284E0ZP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Gâtel et al.

Références

Trends Cell Biol. 2019 Sep;29(9):704-716
pubmed: 31300189
Cell Rep. 2014 Jun 26;7(6):1815-23
pubmed: 24910433
Trends Biochem Sci. 2017 Nov;42(11):873-886
pubmed: 28947091
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):
pubmed: 28847818
F1000Res. 2017 Jul 28;6:1273
pubmed: 28794865
Cancer Res. 2018 May 15;78(10):2601-2613
pubmed: 29487199
Nat Rev Mol Cell Biol. 2016 Sep;17(9):581-95
pubmed: 27435506
Semin Cancer Biol. 2016 Feb;36:18-32
pubmed: 26410033
Int J Mol Sci. 2019 Aug 09;20(16):
pubmed: 31405039
Genome Res. 2015 Jun;25(6):897-906
pubmed: 25800674
Bioinformatics. 2016 May 15;32(10):1577-9
pubmed: 26803161
Best Pract Res Clin Haematol. 2017 Dec;30(4):341-355
pubmed: 29156207
PLoS One. 2010 Jun 28;5(6):e11332
pubmed: 20596523
Nat Rev Cancer. 2017 Mar;17(3):184-197
pubmed: 28134258
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2543-8
pubmed: 19181856
Science. 1989 Mar 24;243(4898):1576-83
pubmed: 2538923
Expert Rev Proteomics. 2018 Mar;15(3):245-258
pubmed: 29376447
Cell Stem Cell. 2018 Nov 1;23(5):742-757.e8
pubmed: 30401455
Physiol Rev. 2002 Apr;82(2):373-428
pubmed: 11917093
Int J Biochem Cell Biol. 2018 Aug;101:80-93
pubmed: 29864543
Blood. 2016 Jan 7;127(1):53-61
pubmed: 26660429
Biochem Soc Trans. 2017 Oct 15;45(5):1137-1148
pubmed: 28939693
Methods Enzymol. 2005;398:20-32
pubmed: 16275316
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Oncogene. 2014 Feb 13;33(7):921-7
pubmed: 23396363
Am J Hematol. 2012 Jan;87(1):89-99
pubmed: 22180162
Anal Biochem. 2005 Aug 15;343(2):313-21
pubmed: 15993367
J Biol Chem. 2001 Sep 21;276(38):35368-74
pubmed: 11451954
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Transcription. 2017 Aug 8;8(4):220-231
pubmed: 28379052
Genome Res. 2013 Oct;23(10):1563-79
pubmed: 23893515
Gut. 2020 Jan 30;:
pubmed: 32001555
Annu Rev Biophys. 2014;43:357-79
pubmed: 24773014
Apoptosis. 2017 Dec;22(12):1487-1509
pubmed: 29067538
Cancer Lett. 2016 Nov 28;382(2):231-239
pubmed: 27561426
Transl Cancer Res. 2016 Dec;5(6):707-724
pubmed: 28690977
Blood. 2014 Sep 25;124(13):2081-90
pubmed: 25143484
Nat Cell Biol. 2016 May 27;18(6):579-86
pubmed: 27230526
Blood. 2010 Apr 8;115(14):2827-34
pubmed: 19965618
Oncotarget. 2017 Jul 25;8(30):49783-49795
pubmed: 28572537
Mol Syst Biol. 2007;3:116
pubmed: 17551511

Auteurs

Pierre Gâtel (P)

Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Frédérique Brockly (F)

Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Christelle Reynes (C)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France.
BioCampus Montpellier (BCM), University of Montpellier, CNRS, INSERM, Montpellier, France.

Manuela Pastore (M)

BioCampus Montpellier (BCM), University of Montpellier, CNRS, INSERM, Montpellier, France.

Yosr Hicheri (Y)

Département d'Hématologie Clinique, CHU de Montpellier, Montpellier, France.

Guillaume Cartron (G)

Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France.
Département d'Hématologie Clinique, CHU de Montpellier, Montpellier, France.

Marc Piechaczyk (M)

Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Guillaume Bossis (G)

Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France guillaume.bossis@igmm.cnrs.fr.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH